Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2026-06-02 16:30:18 ET · period of report 2026-06-01 · accession 0001238120-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-02 16:30 | 2026-06-01 | TSHA | Donenberg Phillip B. | Dir | A - Grant | $0.00 | +21.3K | 241.3K | +10% | $0 |
| D | 2026-06-02 16:30 | 2026-06-01 | TSHA | Donenberg Phillip B. | Dir | A - Grant | $0.00 | +42.7K | 42.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | A | A | 21,335 | $0.00 | 241,289 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-06-01 | A | A | 42,671 | $0.00 | 42,671 | D | $5.97 · — to 2036-06-01 | 42,671 Common Stock | (F2) The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |